Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 10 August 2017

Active Biotech AB - Interim report January - June 2017

Active Biotech    

Published: 08:30 CEST 10-08-2017 /GlobeNewswire /Source: Active Biotech / : ACTI /ISIN: SE0001137985

Active Biotech AB - Interim report January - June 2017

  

Second quarter in brief

  • In April, the US Food and Drug Administration (FDA) granted Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
  • The primary clinical endpoint from the Phase III trial of laquinimod in RRMS (CONCERTO study) was not met. The secondary endpoints (brain atrophy, relapse rate and MRI-data) were achieved and in line with previous studies
  • Out-licensing activities are continuing for tasquinimod, paquinimod and SILC

 

Events after the end of the period

  • Helén Tuvesson succeeds Tomas Leanderson as President & CEO of the company July 1, 2017
  • In July, a patent application for the use of ANYARA in combination with PD-1 inhibitors for the treatment of cancer was published on WIPO's (World Intellectual Property Organization) website www.wipo.int
     

Financial summary

SEK M

April-June

Jan.-June

Full-year

 

2017

2016

2017

2016

2016

 

 

 

 

 

 

Net sales

5.1

3.9

9.8

7.9

19.0

Operating loss

-23.1

-14.5

-37.7

-30.6

-55.1

Loss for the period

-24.4

-15.5

-40.2

-32.3

-59.6

Loss per share, before and after dilution (SEK)

-0.25

-0.17

-0.42

-0.36

-0.65

Cash and cash equivalents (at the end of the period)

 

 

47.7

57.4

77.7

 

 

For further information, please contact:

  Helén Tuvesson, President & CEO

  Tel: +46 (0)46-19 21 56

 

  Hans Kolam, CFO

  Tel: +46 (0)46 19 20 44

 

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: 046 (0)46-19 20 00

 

The report is also available at www.activebiotech.com.



Active Biotech AB - Interim report January – June 2017



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Active Biotech, Scheelevägen 22
Box 724, LUND 220 07,
If you would like to unsubscribe and stop receiving these e-mails click here.